Drug Trial Radar · NCT02604836
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
Last checked: Nov 20, 2026Latest source record: Nov 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,711
Actual
Start
Jun 2004
Primary completion
Apr 2006
Study completion Apr 2006
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 13, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or risedronate. The anticipated time on study treatment is 6 months, and the target sample size is 1776 individuals.
Conditions
- Postmenopausal Osteoporosis
Interventions
IbandronateDrug
Film-coated oral ibandronate tablet (150 mg) once-monthly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of participants who currently use weekly biphosphonate who answer "yes" to any of the questions in Candidate Identification Questionnaire (CIQ)Time frame: Up to 30 days prior to baseline visit
- Part B: Number of participants who demonstrate improvement from their baseline satisfaction score after 6 months of ibandronateTime frame: 6 months
- Part B: Percentage of participants who demonstrate improvement from their baseline satisfaction score after 6 months of ibandronateTime frame: 6 months
Locations
142 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Columbiana, Alabama
Site not named
Huntsville, Alabama
Site not named
Mobile, Alabama
Site not named
Montgomery, Alabama
Site not named
Chandler, Arizona
Site not named
Gilbert, Arizona
Site not named
Paradise Valley, Arizona
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
Tempe, Arizona
Site not named
Tucson, Arizona
Site not named
Carlisle, Arkansas
Site not named
Jonesboro, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Pine Bluff, Arkansas
Site not named
Rogers, Arkansas
Site not named
Searcy, Arkansas
Site not named
Sherwood, Arkansas
Site not named
Anaheim, California
Site not named
Beverly Hills, California
Site not named
Laguna Hills, California
Site not named
Mission Viejo, California
Site not named
Palm Desert, California
Site not named
Palo Alto, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Tacoma, California
Site not named
Vista, California
Site not named
Westlake Village, California
Site not named
Colorado Springs, Colorado
Site not named
Lakewood, Colorado
Site not named
Avon, Connecticut
Site not named
Cromwell, Connecticut
Site not named
Hamden, Connecticut
Site not named
New London, Connecticut
Site not named
Waterbury, Connecticut
Site not named
Wilmington, Delaware
Site not named
Aventura, Florida
Site not named
Clearwater, Florida
Showing 40 of 142 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.